TGR BioSciences

Executive Summary

TGR BioSciences is an Australian immunoassay company leveraging its patented CaptSure™ antibody immobilisation platform to develop fast, no-wash, bead-based assays. Its flagship SureFire® Ultra™ AlphaLISA products enable high-throughput phosphoprotein detection for drug discovery, and the platform extends to ELISA, lateral flow, IHC, and microfluidics. The company licenses its technology and partners with global life-science firms to expand multiplexing and diagnostic applications. Founded in 2020, TGR has raised $8M and employs 50-200 staff, positioning itself as a key enabler in the immunoassay market. With its proprietary platform, TGR addresses the growing demand for sensitive, multiplexed assays in oncology and immunology. The company's technology offers advantages in speed, sensitivity, and scalability, appealing to both research and clinical diagnostic markets. As it continues to expand its product portfolio and forge partnerships, TGR is poised to capture a significant share of the immunoassay market, estimated to reach $30B by 2027. The company's asset-light licensing model provides scalability and attractive margins.

Upcoming Catalysts (preview)

• Q3 2026Launch of new multiplex assay product60% success
• H2 2026Strategic partnership with global pharma company50% success
• TBDSeries B funding round70% success